# Evaluation of Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT 1) and H19 in Determining the Diagnosis and Severity of the Disease in Patients with Acute Pancreatitis

## TL;DR

This study explores whether two non-coding RNAs, MALAT1 and H19, can help diagnose acute pancreatitis and assess its severity.

## Contribution

The study identifies MALAT1 as a potential biomarker for diagnosing acute pancreatitis.

## Key findings

- MALAT1 expression was significantly upregulated in acute pancreatitis patients compared to healthy individuals.
- H19 levels did not differ between acute pancreatitis patients and healthy individuals.
- Neither MALAT1 nor H19 correlated with the severity of acute pancreatitis.

## Abstract

This current research targeted to assess whether long non-coding RNAs MALAT1 and H19, which are accepted to act a pivotal role in the progression of acute pancreatitis (AP), can be used as candidate biomarkers in addressing the diagnosis and severity of AP.

Healthy volunteers who applied to the Internal Medicine outpatient clinic between October 2022 and June 2023 and patients who were hospitalized and treated for AP in the same period were enrolled in the research. The sociodemographic characteristics, biochemical values, and expression levels of MALAT1 and H19 of the study participants were compared.

There was no difference in terms of H19 level among the patient and healthy individuals (P = .619). However, a marked upregulation of MALAT1 expression was observed in cases of AP (P = .018). In addition, a range of biochemical markers showed notable disparities between the patient cohort and healthy individuals.

According to the results of this current study, because the MALAT1 levels were significantly increased in AP cases, it could be postulated that MALAT1 can be used as a candidate biomarker in AP cases in order to diagnose the illness. However, MALAT1 and H19 did not correlate with the severity of the disease.